Clinical trial
Safety and Efficacy of Insulin Glargine Injection [rDNA Origin] Treatment in Place of the TZD or the Sulfonylurea or Metformin in Triple Agent Therapy for T2DM Adult Subjects With Unsatisfactory Control
NCT00283049 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of Insulin Glargine Injection [rDNA Origin] Treatment in Place of the TZD or the Sulfonylurea or Metformin in Triple Agent Therapy for T2DM Adult Subjects With Unsatisfactory Control
- Lead sponsor
- Sanofi
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- February 28, 2006
- Completion date
- November 30, 2008
- Enrollment
- 390 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.